Enhancing antibody efficacy in plants via targeted manipulation of dolichol biosynthesis

PlantForm Corporation是一家加拿大公司，专门将植物转化为多功能的“生物反应器”，用于生产治疗艾滋病毒/艾滋病、乳腺癌和其他形式癌症的治疗性蛋白质。与目前用于生产蛋白质治疗药物的动物系统相比，PlantForm的植物生产系统大大降低了生产成本。PlantForm单克隆抗体生产效率的任何进步不仅将使他们在这个价值数十亿美元的生物制药市场上具有竞争优势，而且降低生产成本将降低成千上万受此类疾病影响的加拿大人的治疗成本。该研究项目的目标是通过整合圭尔夫大学Tariq Akhtar博士最近开发的技术来增强PlantForm的生物生产平台。具体而言，该研究项目旨在提高可在植物中生产的功能性单克隆抗体的产量。

PlantForm Corporation is a Canadian company that specializes in turning plants into versatile 'bioreactors' for the production of therapeutic proteins used in the treatment of HIV/AIDS, breast and other forms of cancer. Compared to current animal systems that are used to produce protein based therapeutics, PlantForm's plant-based production system lowers the manufacturing costs considerably. Any advancement in PlantForm's mAbs production efficiency will not only give them a competitive edge in this billion dollar biopharmaceutical market, but lower production costs translate into lower treatment costs for the thousands of Canadians who are affected by such diseases. The objective of this research project is to enhance PlantForm's bioproduction platform by incorporating technology that has recently been developed by Dr. Tariq Akhtar at the University of Guelph. Specifically, this research project aims to improve the yield of functional monoclonal antibodies that can be produced in plants.